The recombinant chaperone vaccine (e.g., hsp110-gp100) that is built on the superior antigen-carrying and delivering property of the evolutionarily conservative HSPs can efficiently generate antitumor immune responses in preclinical cancer models (5, 8). Here, HSPH1 is linked to cancer.